This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (64)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Quality of Care  • Quality of Care, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

David C. Radley, MPH; Stan N. Finkelstein, MD; Randall S. Stafford, MD, PhD

Arch Intern Med. 2006;166:1021-1026.

Background  Unlike medicines prescribed for Food and Drug Administration–approved indications, off-label uses may lack rigorous scientific scrutiny. Despite concerns about patient safety and costs to the health care system, little is known about the frequency of off-label drug use or the degree of scientific evidence supporting this practice.

Methods  We used nationally representative data from the 2001 IMS Health National Disease and Therapeutic Index (NDTI) to define prescribing patterns by diagnosis for 160 commonly prescribed drugs. Each reported drug-diagnosis combination was identified as Food and Drug Administration–approved, off-label with strong scientific support, or off-label with limited or no scientific support. Outcome measures included (1) the proportion of uses that were off-label and (2) the proportion of off-label uses supported by strong scientific evidence. Multivariate analyses were used to identify drug-specific characteristics predictive of increased off-label use.

Results  In 2001, there were an estimated 150 million (95% confidence interval, 127-173 million) off-label mentions (21% of overall use) among the sampled medications. Off-label use was most common among cardiac medications (46%, excluding antihyperlipidemic and antihypertensive agents) and anticonvulsants (46%), whereas gabapentin (83%) and amitriptyline hydrochloride (81%) had the greatest proportion of off-label use among specific medications. Most off-label drug mentions (73%; 95% confidence interval, 61%-84%) had little or no scientific support. Although several functional classes were associated with increased off-label use (P<.05), few other drug characteristics predicted off-label prescription.

Conclusions  Off-label medication use is common in outpatient care, and most occurs without scientific support. Efforts should be made to scrutinize underevaluated off-label prescribing that compromises patient safety or represents wasteful medication use.

Author Affiliations: Center for Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, NH (Mr Radley); Program on the Pharmaceutical Industry, Sloan School of Management, Massachusetts Institute of Technology, Cambridge (Dr Finkelstein); and Program on Prevention Outcomes and Practices, Stanford Prevention Research Center, Stanford, Calif (Dr Stafford). Dr Finkelstein is now additionally with Harvard Medical School, Boston, Mass.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Critical Review of the Determination Process by the Japanese Reviewing Authority in Approving the Additional Efficacy of Fludarabine Phosphate
Narimatsu et al.
JCO 2009;27:e236-e238.
FULL TEXT  

Going Off-label Without Venturing Off-Course: Evidence and Ethical Off-label Prescribing
Largent et al.
Arch Intern Med 2009;169:1745-1747.
FULL TEXT  

Pharmacists' role in facilitating evidence-based prescribing for unlabeled use of medications
Macaulay et al.
Am J Health Syst Pharm 2009;66:1735-1739.
FULL TEXT  

Off-Label Use of Antipsychotic Medications in the Department of Veterans Affairs Health Care System
Leslie et al.
Psychiatr. Serv. 2009;60:1175-1181.
ABSTRACT | FULL TEXT  

Off-label prescribing: a call for heightened professional and government oversight.
Dresser and Frader
J Law Med Ethics 2009;37:476-486.
 

Just a Spoonful of Sugar: Drug Safety for Pediatric Populations
Noah
J Law Med Ethics 2009;37:280-291.
 

Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals
Mello et al.
NEJM 2009;360:1557-1566.
FULL TEXT  

Systematic Review: Reliability of Compendia Methods for Off-Label Oncology Indications
Abernethy et al.
ANN INTERN MED 2009;150:336-343.
ABSTRACT | FULL TEXT  

Controlling Off-Label Medication Use
Gillick
ANN INTERN MED 2009;150:344-347.
ABSTRACT | FULL TEXT  

Commentary: Risk/Benefit Ratio of Androgen Deprivation Treatment for Sex Offenders
Berlin
J Am Acad Psychiatry Law 2009;37:59-62.
ABSTRACT | FULL TEXT  

Cardiac Resynchronization Therapy for Heart Failure: A Hammer in Search of Nails
McAlister
Circulation 2008;118:901-903.
FULL TEXT  

Who Are the New Users of Antipsychotic Medications?
Domino and Swartz
Psychiatr. Serv. 2008;59:507-514.
ABSTRACT | FULL TEXT  

FDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors
Psaty and Ray
JAMA 2008;299:1949-1951.
FULL TEXT  

Pharmaceutical Promotion to Physicians and First Amendment Rights
Kesselheim and Avorn
NEJM 2008;358:1727-1732.
FULL TEXT  

Regulating Off-Label Drug Use -- Rethinking the Role of the FDA
Stafford
NEJM 2008;358:1427-1429.
FULL TEXT  

Gabapentin: a multimodal perioperative drug?
Kong and Irwin
Br J Anaesth 2007;99:775-786.
ABSTRACT | FULL TEXT  

Indication creep: physician beware
Hebert and Stanbrook
CMAJ 2007;177:697-697.
FULL TEXT  

L'expansion des indications : medecins, attention
Hebert and Stanbrook
CMAJ 2007;177:699-699.
FULL TEXT  

What Cannot Be Said on Television About Health Care
Emanuel
JAMA 2007;297:2131-2133.
FULL TEXT  

Positive Outcomes Through the Appropriate Use of Off-Label Prescribing
Bright
Arch Intern Med 2006;166:2554-2555.
FULL TEXT  

Safeguarding Patient Welfare: Who's In Charge?
Henney
ANN INTERN MED 2006;145:305-307.
FULL TEXT